Categories

A sample text widget

Etiam pulvinar consectetur dolor sed malesuada. Ut convallis euismod dolor nec pretium. Nunc ut tristique massa.

Nam sodales mi vitae dolor ullamcorper et vulputate enim accumsan. Morbi orci magna, tincidunt vitae molestie nec, molestie at mi. Nulla nulla lorem, suscipit in posuere in, interdum non magna.

Two cell therapy centers to be open in region by Bioheart

Two Centers of excellence will be established in the region, as US-based Bioheart has planed, in order to provide its cell therapy procedures to patients with congestive heart failure (CHF) and peripheral arterial disease (PAD).31-5-2010-2

Dr Karl Groth, chairman and CEO, Bioheart, said ‘We feel that the Middle East region is a splendid second site for our centers of excellence. There is easy access to both of the sites that we are considering, Jordan and Turkey, from other countries in the Middle East as well as from Europe and South Asia,’ added ‘Increasing economic wealth in the Mena has been accompanied by urbanization. Cardiovascular disease, a corollary to urban life, has been increasing rapidly and is now the region’s leading cause of death, accounting for 25 to 45 per cent of total deaths. Over the past few decades, daily per capita fat consumption has increased in most countries in the region, ranging from a 13.6 per cent increase in the Sudan to a 143.3 per cent increase in Saudi Arabia.’ He explained that ‘Ischemic heart disease is the predominant cause of cardiovascular disease, with about three ischemic heart disease deaths for every stroke death. Also more prevalent in the Middle East than in the rest of the world, rheumatic heart disease remains a major cause of morbidity and mortality, but the number of hospitalizations related to this problem is declining rapidly. Cell technologies have not been used for treatment of rheumatic heart disease, but one can reason that they would be effective.’

The company has begun work in Jordan on its Regen trial, a Phase I Clinical Trial to test genetically modified MyoCell in patients suffering from Congestive Heart Failure (CHF). The first patient is expected to receive treatment in July. The firm also has plans for establishing a cell manufacturing facility in Jordan as well. ‘The facilities and physicians in Jordan and Turkey are comparable to the best facilities and physicians in the United States,’ said Peggy A Farley, chief operating and financial officer. ‘Bioheart has plans for establishing a cell manufacturing facility in Jordan as well,’

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>